Techno-economic analysis of Camelina-derived hydroprocessed renewable jet fuel within the US context

2021 ◽  
Vol 287 ◽  
pp. 116525
Author(s):  
Jacob Shila ◽  
Mary E. Johnson
Keyword(s):  
Economic Analysis ◽  
Jet Fuel ◽  
The Us

Statistical Inference in Economics in the 1920s and 1930s

2021 ◽  
Vol 53 (6) ◽  
pp. 53-80
Author(s):  
Jeff Biddle
Keyword(s):  
United States ◽  
Probability Theory ◽  
Economic Analysis ◽  
Statistical Inference ◽  
Statistical Data ◽  
The United States ◽  
Interesting Case ◽  
Agricultural Products ◽  
Department Of Agriculture ◽  
The Us

Statistical inference is the process of drawing conclusions from samples of statistical data about things not fully described or recorded in those samples. During the 1920s, economists in the United States articulated a general approach to statistical inference that downplayed the value of the inferential measures derived from probability theory that later came to be central to the idea of statistical inference in economics. This approach is illustrated by the practices of economists of the Bureau of Economic Analysis of the US Department of Agriculture, who regularly analyzed statistical samples to forecast supplies of various agricultural products. Forecasting represents an interesting case for studying the development of inferential methods, as analysts receive regular feedback on the effectiveness of their inferences when forecasts are compared with actual events.

scholarly journals Subsidy Determination, Benchmarks, and Adverse Inferences: Assessing ‘Benefit' in US–Coated Paper (Indonesia)

2020 ◽  
Vol 19 (2) ◽  
pp. 216-231
Author(s):  
Eugene Beaulieu ◽  
Denise Prévost
Keyword(s):  
Economic Analysis ◽  
Natural Resources ◽  
Natural Resource ◽  
Benefit Analysis ◽  
Government Ownership ◽  
Coated Paper ◽  
The Us ◽  
Countervailing Duties ◽  
Key Aspects

AbstractThis paper presents a legal-economic analysis of key aspects of the WTO Panel Report involving a challenge by Indonesia against the anti-dumping and countervailing duties imposed by the US on certain coated paper from Indonesia. We focus on the findings in this case relevant to the determination of a ‘benefit’ to the recipient, a core requirement to establish the existence and extent of a subsidy. We examine benchmarking for determining benefit in cases of predominant government ownership of a natural resource and the use of ‘adverse facts available’ against a non-cooperative respondent to infer the existence of a benefit. The benefit analysis in this case may have broader implications. First, it may limit the scope for governments to determine their own policies regarding the ownership and management of natural resources. Second, it may create a loophole allowing investigating authorities to fill gaps in the factual record by intentionally using the ‘facts available’ to the disadvantage of a respondent. In both cases, the panel's findings may open the door to potential misuse of these flexibilities to find a benefit where none exists, or to inflate the margin of benefit to allow for higher countervailing duties.

scholarly journals Economic analysis and budget impact of clostridial collagenase ointment compared with medicinal honey for treatment of pressure ulcers in the US

2017 ◽  
Vol Volume 9 ◽  
pp. 485-494 ◽  
Author(s):  
Elizabeth S Mearns ◽  
Michael Liang ◽  
Brendan Limone ◽  
Adrienne M. Gilligan ◽  
Jeffrey D. Miller ◽  
...  
Keyword(s):  
Economic Analysis ◽  
Pressure Ulcers ◽  
Budget Impact ◽  
The Us

Self-employment by US county: key predictors

2020 ◽  
Vol 14 (4) ◽  
pp. 583-602
Author(s):  
Nichole M. Bignall ◽  
Keith G. Debbage
Keyword(s):  
Economic Analysis ◽  
Linear Regression Analysis ◽  
Content Type ◽  
Self Employment ◽  
Strong Positive Relationship ◽  
The Us ◽  
Us Counties ◽  
Us Census ◽  
Employment Data

Purpose Some US counties are more likely to generate entrepreneurial opportunities than others. This paper aims to determine the linkages between US counties with disproportionately high shares of entrepreneurs and specific attributes of the entrepreneurial support system. Design/methodology/approach Non-farm proprietorship (NFP) has been used as a proxy for entrepreneurship and self-employment. NFP employment data were collected from the US Bureau of Economic Analysis by county. Data on all independent variables were obtained from the US Census and Bureau of Economic Analysis by county and subject to stepwise linear regression analysis. Findings Results revealed a strong positive relationship between the percent of NFP employment by county and the percent real estate, rental and leasing employment and construction employment as well as percent Hispanic and median age. Practical implications In attempting to encourage NFP employment, policymakers should be more aware of the key predictors that shape county-wide entrepreneurial ecosystems to enhance competitive advantage. Better understanding of the needs and experiences of different types of entrepreneurs and ecosystems can enhance overall quality of life and economic opportunity levels in a community. Originality/value The explicit spatial context of this paper has sometimes been overlooked in the traditional entrepreneurship literature, as such, this paper helps fill that gap. The findings provide a disaggregated analysis that can help better understand the key predictors that can drive the local choices of entrepreneurs and help local policymakers to build more competitive communities.

A Feminist Political Economic Analysis of the US Chicken Industry

Development ◽  
2008 ◽  
Vol 51 (4) ◽  
pp. 547-554 ◽  
Author(s):  
Kristin Sampson
Keyword(s):  
Economic Analysis ◽  
The Us ◽  
Political Economic

An economic analysis of axitinib and sorafenib for second-line treatment of cytokine-refractory patients with advanced renal cell carcinoma in the United States (US).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15601-e15601
Author(s):  
Ipek Özer-Stillman ◽  
Apoorva Ambavane ◽  
Paul Cislo
Keyword(s):  
Economic Analysis ◽  
The United States ◽  
Phase Iii ◽  
Administrative Claims ◽  
Line Treatment ◽  
Second Line ◽  
Cost Difference ◽  
Life Years ◽  
The Us ◽  
The Cost

e15601 Background: Cytokines are a first-line treatment option for a subset of advanced RCC patients in the US. After progression on cytokines, NCCN guidelines recommend targeted agents, such as axitinib and sorafenib. Subgroup analysis of post-cytokine patients in the phase III AXIS trial found that axitinib increased median progression free survival (PFS) compared with sorafenib (12.0 vs. 6.6 months, p<0.0001), while overall survival (OS) showed no difference (29.4 vs. 27.8 months, p=0.144). An economic analysis for this subgroup was conducted from a US healthcare payer perspective. Methods: A cohort partition model with monthly cycles was constructed to estimate direct medical costs and health outcomes, discounted at 3.0% per annum, over cohort lifetime. Patients were apportioned into 3 health states (progression-free, progressed and dead) based on OS and PFS Kaplan-Meier curves for the post-cytokine subgroup in the AXIS trial. Active treatment was applied until progression, followed by best supportive care (BSC) alone thereafter. The wholesale acquisition costs were based from RedBook. Adverse event (AE) management costs were obtained from published studies. AE rates and utility values were informed by the AXIS trial. Administrative claims data from MarketScan Database were analyzed to estimate costs for BSC and routine care of second-line advanced RCC patients. Results: The total per-patient lifetime costs were estimated to be $242,750 for axitinib and $168,880 for sorafenib and most of the cost difference (84%) was due to the higher total medication cost of axitinib. The cost difference was sensitive to dose intensity and length of treatment. The difference in quality-adjusted life-years (QALY) for axitinib versus sorafenib was minor (1.3 versus 1.2) and the incremental cost-effectiveness ratio (ICER) for axitinib compared with sorafenib was $683,209/QALY. Conclusions: For cytokine-refractory advanced RCC patients, axitinib resulted in an ICER > $650,000/QALY versus sorafenib due to high drug costs and lack of OS benefit, indicating that axitinib may not present good value for money as 2nd line treatment when compared to sorafenib in the US.

Sign in / Sign up

Export Citation Format

Share Document